A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide

Glioblastoma (GBM) is the most malignant glioma, with a median overall survival (OS) of 14–16 months. Temozolomide (TMZ) is the first-line chemotherapy drug for glioma, but whether TMZ should be withheld from patients with GBMs that lack O6-methylguanine-DNA methyltransferase (MGMT) promoter methyla...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Rui-Chao, Chang, Yu-Zhou, Wang, Qiang-Wei, Zhang, Ke-Nan, Li, Jing-Jun, Huang, Hua, Wu, Fan, Liu, Yu-Qing, Wang, Yong-Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776832/
https://www.ncbi.nlm.nih.gov/pubmed/31611911
http://dx.doi.org/10.3389/fgene.2019.00910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776832/
https://www.ncbi.nlm.nih.gov/pubmed/31611911
http://dx.doi.org/10.3389/fgene.2019.00910

Ejemplares similares